Exagen/$XGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Exagen
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
Ticker
$XGN
Sector
Primary listing
Employees
218
Headquarters
Website
Exagen Metrics
BasicAdvanced
$73M
-
-$0.93
1.91
-
Price and volume
Market cap
$73M
Beta
1.91
52-week high
$12.23
52-week low
$2.59
Average daily volume
281K
Financial strength
Current ratio
3.453
Quick ratio
3.042
Long term debt to equity
141.338
Total debt to equity
158.553
Interest coverage (TTM)
-3.26%
Profitability
EBITDA (TTM)
-11.952
Gross margin (TTM)
58.28%
Net profit margin (TTM)
-29.97%
Operating margin (TTM)
-21.13%
Effective tax rate (TTM)
-0.26%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-17.12%
Return on equity (TTM)
-147.85%
Valuation
Price to revenue (TTM)
0.981
Price to book
3.98
Price to tangible book (TTM)
3.98
Price to free cash flow (TTM)
-4.579
Free cash flow yield (TTM)
-21.84%
Free cash flow per share (TTM)
-0.662
Growth
Revenue change (TTM)
19.65%
Earnings per share change (TTM)
11.45%
3-year revenue growth (CAGR)
13.47%
10-year revenue growth (CAGR)
14.01%
3-year earnings per share growth (CAGR)
-30.64%
10-year earnings per share growth (CAGR)
-44.59%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Exagen stock?
Exagen (XGN) has a market cap of $73M as of April 13, 2026.
What is the P/E ratio for Exagen stock?
The price to earnings (P/E) ratio for Exagen (XGN) stock is 0 as of April 13, 2026.
Does Exagen stock pay dividends?
No, Exagen (XGN) stock does not pay dividends to its shareholders as of April 13, 2026.
When is the next Exagen dividend payment date?
Exagen (XGN) stock does not pay dividends to its shareholders.
What is the beta indicator for Exagen?
Exagen (XGN) has a beta rating of 1.91. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.